Advertisement
Demo

Merck, Pfizer combo treatment boosts kidney cancer survival

Feb 12, 2019 , Reuters
Drugmaker Merck & Co Inc said on Monday that the combination of its cancer immunotherapy Keytruda with Pfizer Inc's Inlyta cut the risk of death nearly in half for patients with the most common form of kidney cancer when compared with treatment with chemotherapy drug Sutent.


Read the full story...


Trending healthcare news keywords at this moment

mental fda cancer drug kids cdc outbreak disease test digital marketing media years life care study tip blood state bill medical healthcare launches salmonella states people finds linked age buy measles cases higher risk therapy sleep good diabetes opioid patients heart children york generic food raises doctors